Valion Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 28, 2026, specifically the 2026 Annual Meeting of Stockholders held in a virtual format. Valion Bio, Inc. is a Delaware corporation with its principal executive offices in San Antonio, Texas, and its common stock trades on The Nasdaq Stock Market under the symbol VBIO. The company is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity matters; it does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The filing notes that as of the record date (April 24, 2026), there were 3,139,095 shares of common stock issued and outstanding. Holders of Series A, B, and C Non-Voting Convertible Preferred Stock were not entitled to vote on the matters presented.
Material Changes and Voting Results
At the Annual Meeting, approximately 50.0% of outstanding common stock was represented, establishing a quorum. Stockholders approved the following key proposals:
- Proposal 1 (Director Election): Elected Dean Zikria as a Class II director (873,001 votes for).
- Proposal 2 (Equity Plan Amendment): Approved an amendment to the 2021 Equity Incentive Plan to increase the authorized share pool by 2,581,608 shares. This amendment became effective immediately upon approval.
- Proposal 3 (Auditor Ratification): Ratified Rosenberg Rich Baker Berman, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposals 4-7 (Nasdaq Listing Approvals): Approved the issuance of common stock upon conversion of preferred stock and exercise of warrants related to Securities Purchase Agreements with institutional investors (including 3i, LP and Tumim Stone Capital, LLC) and a Senior Secured Convertible Note. These approvals were required under Nasdaq Listing Rule 5635(d).
- Proposal 8 (Adjournment): Approved the authority to adjourn the meeting if necessary, though the Chair did not exercise this option as all proposals passed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard incorporation by reference to the Definitive Proxy Statement filed on April 30, 2026. The approval of Proposals 4 through 7 indicates the company is proceeding with capital raise mechanisms involving convertible instruments and warrants with institutional investors.
Key Facts for Investor Verification
- Verify the impact of the 2,581,608 share increase to the 2021 Equity Incentive Plan on potential future dilution.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 30, 2026, for full details on the terms of the Securities Purchase Agreements referenced in Proposals 4-7.
- Confirm the conversion terms and warrant exercise prices associated with the Series B and C Preferred Stock and the Senior Secured Convertible Note approved for issuance.
- Note that 311,474 shares were excluded from voting on Proposals 4-7 due to Nasdaq listing rules regarding the investors' holdings.